INVESTMENTS TO ADDRESS HEALTH INEQUITIES IN PROSTATE CANCER CARE Movember funds three Australian programs targeting under-served populations
SEGMENT
Filmed in Melbourne | February 2025
INTERVIEWS
Sarah Weller
Global Director – Prostate Cancer, Movember
Kris Bennett,
Director – Prostate Cancer Health Equity, Movember
Movember is committed to advancing new research, cutting-edge treatments, and healthy behaviours, and advocating for inclusive, gender-responsive healthcare that caters to the unique needs of men, women, and gender-diverse individuals from diverse cultural backgrounds. In doing so, they hope to forge a future where barriers to healthy living are overcome, stigmas are removed, and where everyone has an equal opportunity to live a long, healthy life.
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
AUSTRALIAN FUNDING FOR TARGETED PROSTATE CANCER CARE OUTREACH PROGRAMS
– The prostate cancer mortality rate in remote areas is almost 20% higher than in major cities. Access to treatment is the leading cause. This equity gap is what the Royal Flying Doctor Service of Australia’s grant will address, to improve access to and use of prostate cancer treatment services in rural and remote areas.
– Currently, prostate cancer data on the culturally and linguistically diverse communities of South Western Sydney is insufficient. That’s the first roadblock to improving this historically overlooked group’s prostate cancer care. The George Institute for Global Health aims to fill in the blanks with population level data to help close this equity gap.
– Australian Prostate Centre will create culturally appropriate prostate cancer services and practices for the LGBTQIA+ community, to counter the fear of discrimination and stigma that often stands in its way of getting prostate cancer screenings and diagnoses.
Australian Health Journal spoke with Movember about these targeted outreach programs in Australia and the hope they will help provide education and empower historically and intentionally excluded communities, using community stakeholders and voices to build trust. Collaborations with healthcare providers, academic institutions, and community-based organisations will share resources and expertise to develop tailored solutions.
-
Surgeon-scientist path laid for medical device research
In 2022, Distinguished Professor Gordon Wallace AO and Professor Mukherjee jointly established Beyond Science as a clinician led, academically supported and clinician run Australian-first medical technology translation program.
The program is aimed at early career researchers and clinician-scientists working in medical device research specifically in otolaryngology (ear, nose, and throat), head and neck surgery.
-
Spinal implant technology eyes global opportunity
Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
